Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) has started a new share repurchase program worth up to €50 million after completing its initial program on October 16, 2026. The initial program, announced on June 9, 2026, bought approximately 1.99 million ordinary shares for €50 million, with the shares held as treasury shares. The new program may cover up to 4,604,550 ordinary shares and began on November 16, 2026. Morgan Stanley & Co International PLC will execute purchases independently under a discretionary mandate in the open market on Euronext, under terms approved by Lakefront’s Extraordinary Shareholders’ Meeting on April 28, 2026. The program ends on the earlier of March 31, 2027, or completion of the mandate. Lakefront said the shares can support obligations under its equity-based incentive programs and that regular updates will be published. Chief Financial Officer Aaron Cox said the company believes its current share price does not reflect the value of its business and future prospects, while the additional buyback allows it to pursue shareholder value alongside investment in its pipeline. Lakefront may suspend or stop the program at any time and will disclose such a decision. The company describes itself as a biotechnology developer focused on serious diseases and high unmet need, with a clinical-stage immunology and inflammation portfolio anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases.